Astrazeneca plc ADR (NASDAQ: AZN) Shares Declined By -11.23% In One Month.

In the last trading session, 11.29 million Astrazeneca plc ADR (NASDAQ:AZN) shares changed hands as the company’s beta touched 0.51. With the company’s per share price at $61.41 changed hands at -$0.85 or -1.37% during last session, the market valuation stood at $190.39B. AZN’s last price was a discount, traded about -24.67% off its 52-week high of $76.56. The share price had its 52-week low at $61.70, which suggests the last value was -0.47% down since then. When we look at Astrazeneca plc ADR’s average trading volume, we note the 10-day average is 9.82 million shares, with the 3-month average coming to 1.88.

Astrazeneca plc ADR (NASDAQ:AZN) trade information

Instantly AZN was in red as seen at the end of in last trading. With action -5.73%, the performance over the past five days has been red. The drop to weekly highs of 67.08 subtracted -1.37% to the stock’s daily price. The company’s shares are showing year-to-date downside of -8.82%, with the 5-day performance at -5.73% in the red. However, in the 30-day time frame, Astrazeneca plc ADR (NASDAQ:AZN) is -11.23% down. Looking at the short shares, we see there were 4.1 million shares sold at short interest cover period of 0.72 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Astrazeneca plc ADR (AZN) estimates and forecasts

Data shows that the Astrazeneca plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -12.73% over the past 6 months, a 12.67% in annual growth rate that is considerably higher than the industry average of 5.00%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Astrazeneca plc ADR will fall -5.20%, while the growth in revenue is estimated to hit -2.80% for the next quarter. Year-over-year growth is forecast to reach 10.90% up from the last financial year.

Consensus estimates given by 4 financial analysts project the company’s revenue in the current quarter to hit an average of $11.98 billion. 3 analysts are of the opinion that Astrazeneca plc ADR’s revenue for the quarter ending Jun 2024 will be $12.43 billion. The company’s revenue for the corresponding quarters a year ago was $10.55 billion and $10.96 billion respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 13.50%. The estimates for the next quarter sales put growth at 13.40%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 17.72%. The 2024 estimates are for Astrazeneca plc ADR earnings to increase by 13.48%, but the outlook for the next 5-year period is at 13.10% per year.

AZN Dividends

Astrazeneca plc ADR is expected to release its next quarterly earnings report in March. The 2.36% annual yield figure for the share gives it an annual dividend of 1.45. It is important to note, however, that the 2.36% dividend yield ratio should serve as a guide only, as you should also take into consideration many other aspects of a company’s operations and fundamentals before making any investment decision.

On Key

Related Posts